Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for aggressive leukemia: drug combo plus transplant targets cure

NCT ID NCT06483906

Recruiting now Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Mar 05, 2026 · Last updated May 22, 2026 · Updated 12 times

Summary

This study tests a new combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a stem cell transplant in people aged 18-55 with intermediate or high-risk acute myeloid leukemia (AML) who have not been treated before. The goal is to see if this approach can improve survival and reduce the chance of the cancer coming back. Participants will receive up to four cycles of the drug combo, and if tests show the leukemia is cleared, they will proceed to a stem cell transplant. The study will track overall survival at 1 and 2 years, as well as side effects like graft-versus-host disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai General hospital,Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA